Clinical Trials Browser

INDUSTRY × Recurrence × mogamulizumab × Clear all

NCT04745234 2024-04-25

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Phase 2 Active not recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous